Clinical trials: Cancer, Advanced Solid Tumors
Advanced Solid Tumors
KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma)
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KXV01 TCR Lentinvivo for patients with advanced solid tumors.
- Trial name
- NCT07596693
- Testing
- KXV01 TCR Lentinvivo Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- TCRx Therapeutics Co.Ltd
Advanced Cancer, Ovarian Cancer
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with nivolumab.
- Conditions
- Advanced Cancer, Ovarian Cancer, Breast Cancer, Lung Cancer
- Trial name
- NCT03667716
- Testing
- COM701, COM701 with Opdivo (Nivolumab).
- Where
- 11 sites in United States
- Volunteers
- 121 people
- Sponsor
- Compugen Ltd
Cancer
A Study of TAVO412 in Patients with Cancer
TAVO412 Phase 1 is an open-label, non-randomized, 2-part Phase I study to examine the safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of TAVO412.
- Trial name
- TAVO412 (NCT05548634)
- Testing
- TAVO412
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Tavotek Biotherapeutics
Melanoma, Head and Neck Squamous Cell Carcinoma
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours.
- Conditions
- Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
- Trial name
- NCT06305247
- Testing
- IPN01194
- Where
- 12 sites in United States, France and 1 more
- Volunteers
- 36 people
- Sponsor
- Ipsen
Advanced Solid Tumor
A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors
This study will evaluate the safety, tolerability, pharmacokinetics and treatment effect of CS1001 in combination with Donafenib in patients with advanced solid tumors.
- Trial name
- NCT04472858
- Testing
- Donafenib, CS1001
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies
- Conditions
- Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT05877599
- Testing
- NT-175
- Where
- 20 sites in United States
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
The purpose of this study is to evaluate the safety and activity of BPX-601 CAR-T cells in participants with previously treated advanced solid tumors (prostate) expressing high levels of prostate stem cell antigen (PSCA).
- Trial name
- NCT02744287
- Testing
- BPX-601, Rimiducid
- Where
- 13 sites in United States
- Volunteers
- 52 people
- Sponsor
- Regeneron Pharmaceuticals
Solid Tumors
Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors
Study of ABT-869 in Combination with Tarceva in Subjects with Solid Tumors
- Trial name
- NCT00754104
- Testing
- ABT-869, Tarceva
- Sponsor
- Abbott
Malignant Solid Tumor
A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ZL-1218 as a single agent and as combination therapy in subjects with…
- Trial name
- NCT05859464
- Testing
- ZL-1218, Pembrolizumab
- Where
- 15 sites in United States, China and 1 more
- Volunteers
- 34 people
- Sponsor
- Zai Lab (Hong Kong), Ltd.
HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC)
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tumors with CCNE1…
- Conditions
- HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
- Trial name
- NCT07029399
- Testing
- NKT5097 CDK2/CDK4 dual degrader, Fulvestrant, Letrozole
- Where
- 18 sites in United States
- Volunteers
- 361 people
- Sponsor
- NiKang Therapeutics, Inc.
Malignant Solid Tumor, Lymphomas
A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma
Phase 1 study to determine safety, tolerability, dose-limiting toxicities (DLTs), and recommended Phase 2 dose of AV-299 administered IV as monotherapy to patients with relapsed or refractory solid tumors, lymphoma, or multiple…
- Conditions
- Malignant Solid Tumor, Lymphomas, Multiple Myeloma
- Trial name
- P05538 (NCT00725634)
- Testing
- AV-299, AV-299 + erlotinib
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Advanced Solid Tumors
Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
This is an open-label, study of MEDI9090 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of MEDI9090 in adult subjects with advanced solid tumors.
- Trial name
- NCT02900157
- Testing
- MEDI9090, Durvalumab
- Where
- 8 sites in United States, Japan
- Volunteers
- 42 people
- Sponsor
- MedImmune LLC
Advanced Solid Tumors
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
The primary objectives of this study are to: Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors Determine the recommended phase 2 dose…
- Trial name
- NCT06131398
- Testing
- AMG 355, Pembrolizumab
- Where
- 25 sites in United States, Australia and 9 more
- Volunteers
- 77 people
- Sponsor
- Amgen
Solid Tumor
A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors
This Phase 1a, single center, open-label, repeat dose study will evaluate the safety, efficacy, and Pharmacokinetics of ascending doses of OBP-801 in patients with advanced solid tumors.
- Trial name
- NCT02414516
- Testing
- OBP-801
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Oncolys BioPharma Inc
Advanced Solid Tumors
Study of TP-3654 in Patients With Advanced Solid Tumors
TP-3654 is an oral PIM inhibitor. This is a Phase 1, open-label, dose-escalation, safety, pharmacokinetics, and pharmacodynamic study, with a purpose of determining the maximum tolerated dose (MTD) and dose-limiting toxicities…
- Trial name
- NCT03715504
- Testing
- TP-3654
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Sumitomo Pharma America, Inc.
Advanced Solid Tumor, Non-small Cell Lung Cancer
A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients
The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of WX-0593 alone in the treatment of advanced cancer.
- Trial name
- NCT03389815
- Testing
- WX-0593 Tablets
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Melanoma, Non-small Cell Lung Cancer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT03329950
- Testing
- CDX-1140, CDX-301, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Advanced Malignant Solid Tumors
A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers
The main objective of this study is to evaluate the Effect of Food on the Pharmacokinetics of CM082 tablet.
- Trial name
- NCT04126668
- Testing
- CM082 with fed or fasting
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AnewPharma
Multiple Myeloma, Diffuse Large B-Cell Lymphoma
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
The main purpose of this first human study with CC-223 is to assess the safety and action of a new class of experimental drug (dual mTOR inhibitors) in patients with advanced tumors unresponsive to standard therapies and to…
- Conditions
- Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma
- Trial name
- NCT01177397
- Testing
- CC-223
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 226 people
- Sponsor
- Celgene
Solid Tumor, Advanced Cancer
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
This is a multipart, open-label, multi-center dose escalation, dose expansion phase I clinical trial designed to evaluate the safety, tolerability, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and preliminary…
- Conditions
- Solid Tumor, Advanced Cancer, Metastatic Cancer, Non Small Cell Lung Cancer
- Trial name
- NCT05076760
- Testing
- MEM-288 Intratumoral Injection, Nivolumab, Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memgen, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.